Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
Status:
Completed
Trial end date:
2018-03-26
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is to evaluate the safety and the efficacy of
Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment.